Digest Réseau Comment ça marche
Réseau
/
Sociétés
Ta
Non vérifié

Takeda Pharmaceutical Company Limited

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueMédecine - DiversSanté

47 communiqués de presse

Voir tous les communiqués de presse
04/05/2026
Industrie
Santé
Science
Industrie pharmaceutique
Médecine - Divers
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
Source
Takeda Pharmaceutical Company Limited
Émetteur
Business Wire
1.00
0
28/03/2026
Événements
Industrie
Web et Réseaux Sociaux
Téléphonie et Divers
Santé
Médecine - Divers
Santé Publique
Science
Industrie pharmaceutique
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
Source
Takeda Pharmaceutical Company Limited
Émetteur
Business Wire
1.00
0
02/03/2026
Industrie
Oncologie
Santé
Hygiène alimentaire
Médecine - Divers
Industrie pharmaceutique
Biotechnologie
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
Source
Takeda Pharmaceutical Company Limited
Émetteur
Business Wire
1.00
0
19/02/2026
Industrie
Santé
Science
Industrie pharmaceutique
Médecine - Divers
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
Source
Takeda Pharmaceutical Company Limited
Émetteur
Business Wire
1.00
0
10/02/2026
Industrie
Hygiène alimentaire
Santé
Industrie pharmaceutique
Médecine - Divers
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
Source
Takeda Pharmaceutical Company Limited
Émetteur
Business Wire
1.00
0
29/01/2026
Biotechnologie
Industrie pharmaceutique
Santé
Oncologie
Marché financier
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
Source
Takeda Pharmaceutical Company Limited
Émetteur
Business Wire
1.00
0
22/01/2026
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Industrie
Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
Source
Takeda Pharmaceutical Company Limited
Émetteur
Business Wire
1.00
0
05/01/2026
Industrie
Oncologie
Santé
Hygiène alimentaire
Médecine - Divers
Industrie pharmaceutique
Biotechnologie
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
Source
Takeda Pharmaceutical Company Limited
Émetteur
Business Wire
1.00
0
18/12/2025
Industrie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
Source
Takeda Pharmaceutical Company Limited
Émetteur
Business Wire
1.00
0
06/12/2025
Marché du travail
Événements
Industrie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
Source
Takeda Pharmaceutical Company Limited
Émetteur
Business Wire
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0